Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model

Neurobiology of Disease

Volumn 20, Issue 2, 2005, Pages 500-508

  Wang, Wenfei ^a   Duan, Wenzhen ^a   Igarashi, Shuichi ^a   Morita, Hokuto ^a   Nakamura, Masayuki ^a   Ross, Christopher A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aggregation; Cell toxicity; Compound screen; Huntingtin; LDH assay; Polyglutamine disease

Indexed keywords

ACIVICIN; APOPTOSIS INHIBITOR; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE INHIBITOR; DEMECLOCYCLINE; DOXYCYCLINE; HUNTINGTIN; ISOPRENALINE; M 50054; MECLOCYCLINE; METACYCLINE; MINOCYCLINE; MUTANT PROTEIN; MYCOPHENOLIC ACID; NEUROPROTECTIVE AGENT; NIPECOTIC ACID; OXYTETRACYCLINE; PROPAFENONE; PROTEIN INHIBITOR; TETRACYCLINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BRAIN NERVE CELL; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG POTENCY; ENZYME ANALYSIS; ENZYME INHIBITION; HEALTH CARE ORGANIZATION; HUNTINGTON CHOREA; MODEL; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; BRAIN; CASPASES; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; L-LACTATE DEHYDROGENASE; MODELS, BIOLOGICAL; MUTATION; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PC12 CELLS; PEPTIDE FRAGMENTS; PEPTIDES; RATS; TRINUCLEOTIDE REPEATS;

EID: 26944458863     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2005.03.026     Document Type: Article

References (44)

1. A. Abbott Neurologists strike gold in drug screen effort Nature 417 2002 109
2. C.T. Aiken, A.J. Tobin, and E.S. Schweitzer A cell-based screen for drugs to treat Huntington's disease Neurobiol. Dis. 16 2004 546 555
3. M. Arrasate, S. Mitra, E.S. Schweitzer, M.R. Segal, and S. Finkbeiner Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death Nature 431 2004 805 810
4. G.P. Bates Huntingtin aggregation and toxicity in Huntington's disease Lancet 361 2003 1642 1644
5. G.P. Bates, L. Mangiarini, and S.W. Davies Transgenic mice in the study of polyglutamine repeat expansion diseases Brain Pathol. 8 1998 699 714
6. G.P. Bates, P. Harper, and L. Jones Neuropsychologocal and neuropsychiatric aspects of Huntington's disease Huntington's Disease Third ed. Oxford Monographs on Medical Genetics Series 2002 62 94
7. M.W. Becher, J.A. Kotzuk, A.H. Sharp, S.W. Davies, G.P. Bates, D.L. Price, and C.A. Ross Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length Neurobiol. Dis. 4 1998 387 397
8. N.F. Bence, R.M. Sampat, and R.R. Kopito Impairment of the ubiquitin-proteasome system by protein aggregation Science 292 2001 1552 1555
9. S.W. Davies, M. Turmaine, B.A. Cozens, M. DiFiglia, A.H. Sharp, C.A. Ross, E. Scherzinger, E.E. Wanker, L. Mangiarini, and G.P. Bates Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation Cell 90 1997 537 548
10. A. Dedeoglu, J.K. Kubilus, T.M. Jeitner, S.A. Matson, M. Bogdanov, N.W. Kowall, W.R. Matson, A.J. Cooper, R.R. Ratan, M.F. Beal, S.M. Hersch, and R.J. Ferrante Therapeutic effects of cystamine in a murine model of Huntington's disease J. Neurosci. 22 2002 8942 8950
11. P.W. Faber, J.R. Alter, M.E. MacDonald, and A.C. Hart Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron Proc. Natl. Acad. Sci. U. S. A. 96 1999 179 184
12. Y.A. Grimbergen, and R.A. Roos Therapeutic options for Huntington's disease Curr. Opin. Investig. Drugs 4 2003 51 54
13. J. Heemskerk, A.J. Tobin, and B. Ravina From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials Nat. Neurosci. 5 2002 1027 1029 Suppl.
14. V. Heiser, E. Scherzinger, A. Boeddrich, E. Nordhoff, R. Lurz, N. Schugardt, H. Lehrach, and E.E. Wanker Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy Proc. Natl. Acad. Sci. U. S. A. 97 2000 6739 6744
15. S.M. Hersch Huntington's disease: prospects from neuroprotective therapy 10 years after the discovery of the causative genetic mutation Curr. Opin. in Neurol. 16 2003 501 506
16. S.M. Hersch, and H.D. Rosas Neuroprotective therapy for Huntington's disease: new prospects and challenges Expert Rev. Neurotherapeutics 1 2001 111 118
17. M.A. Hickey, and M.F. Chesselet The use of transgenic and knock-in mice to study Huntington's disease Cytogenet. Genome Res. 100 2003 276 286
18. M.A. Hickey, and M.F. Chesselet Apoptosis in Huntington's disease Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 255 265
19. E. Hockly, V.M. Richon, B. Woodman, D.L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P.A. Lowden, J.S. Steffan, J.L. Marsh, L.M. Thompson, C.M. Lewis, P.A. Marks, and G.P. Bates Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 100 2003 2041 2046
20. R.E. Hughes, and J.M. Olson Therapeutic opportunities in polyglutamine disease Nat. Med. 7 2001 419 423
21. Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
22. S. Igarashi, H. Morita, K.M. Bennett, Y. Tanaka, S. Engelender, M.F. Peters, J.K. Cooper, J.D. Wood, A. Sawa, and C.A. Ross Inducible PC12 cell model of huntington's disease NeuroReport 14 2003 565 568
23. J.L. Jankowsky, A. Savonenko, G. Schilling, J. Wang, G. Xu, and D.R. Borchelt Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development Curr. Neurol. Neurosci. Rep. 2 2002 457 464
24. M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell, and L. Steinman Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat. Med. 8 2002 143 149
25. S. Kuemmerle, C.A. Gutekunst, A.M. Klein, X.J. Li, S.H. Li, M.F. Beal, S.M. Hersch, and R.J. Ferrante Huntington aggregates may not predict neuronal death in Huntington's disease Ann. Neurol. 46 1999 842 849
26. P.T. Lansbury Jr. Yeast prions: bungee cord domains' balancing act Curr Biol. 9 1999 R845 R847
27. B.R. Leavitt, C.L. Wellington, and M.R. Hayden Recent insights into the molecular pathogenesis of Huntington disease Semin. Neurol. 19 1999 385 395
28. L. Mangiarini, S. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, and G.P. Bates Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice Cell 87 1996 493 506
29. R.M. Murphy Peptide aggregation in neurodegenerative disease Annu. Rev. Biomed. Eng. 4 2002 155 1574
30. M.F. Peters, F.C. Nucifora Jr., J. Kushi, H.C. Seaman, J.K. Cooper, W.J. Herring, V.L. Dawson, T.M. Dawson, and C.A. Ross Nuclear targeting of mutant Huntingtin increases toxicity Mol. Cell. Neurosci. 14 1999 121 128
31. M.A. Poirier, H. Li, J. Macosko, S. Cai, M. Amzel, and C.A. Ross Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization J. Biol. Chem. 277 2002 41032 41037
32. A. Rosenblatt, M.H. Abbott, L.M. Gourley, J.C. Troncoso, R.L. Margolis, J. Brandt, and C.A. Ross Predictors of neuropathological severity in 100 patients with Huntington's disease Ann. Neurol. 54 2003 488 493
33. C.A. Ross Polyglutamine pathogenesis. emergence of unifying mechanisms for huntington's disease and related disorders Neuron 35 2002 819
34. C.A. Ross, and M.A. Poirier Protein aggregation and neurodegenerative disease Nat. Med. 10 2004 S10 S17 Suppl
35. C.A. Ross, R.L. Margolis, A. Rosenblatt, N.G. Ranen, M.W. Becher, and E. Aylward Reviews in molecular medicine: Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA) Medicine 76 1997 305 338
36. F. Saudou, S. Finkbeiner, D. Devys, and M.E. Greenberg Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions Cell 95 1998 55 66
37. G. Schilling, M.W. Becher, A.H. Sharp, H.A. Jinnah, K. Duan, J.A. Kotzuk, H.H. Slunt, T. Ratovitski, J.K. Cooper, N.A. Jenkins, N.G. Copeland, D.L. Price, C.A. Ross, and D.R. Borchelt Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin Hum. Mol. Genet. 8 1999 397 407
38. S. Sipione, and E. Cattaneo Modeling Huntington's disease in cells, flies, and mice Mol. Neurobiol. 23 1 2001 21 51
39. C. Song, G. Perides, and Y.F. Liu Expression of full-length polyglutamine-expanded Huntingtin disrupts growth factor receptor signaling in rat pheochromocytoma (PC12) cells J. Biol. Chem. 277 2002 6703 6707
40. T. Tsuda, Y. Ohmori, H. Muramatsu, Y. Hosaka, K. Takiguchi, F. Saitoh, K. Kato, K. Nakayama, N. Nakamura, S. Nagata, and H. Mochizuki Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia Eur. J. Pharmacol. 433 2001 37 45
41. M. Vila, and S. Przedborski Targeting programmed cell death in neurodegenerative diseases Nat. Rev., Neurosci. 4 2003 365 375
42. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Neuropathological classification of Huntington's disease J. Neuropathol. Exp. Neurol. 44 1985 559 577
43. A. Wyttenbach, J. Swartz, H. Kita, T. Thykjaer, J. Carmichael, J. Bradley, R. Brown, M. Maxwell, A. Schapira, T.F. Orntoft, K. Kato, and D.C. Rubinsztein Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease Hum. Mol. Genet. 10 2001 1829 1845
44. H. Zhou, F. Cao, Z. Wang, Z.X. Yu, H.P. Nguyen, J. Evans, S.H. Li, and X.J. Li Huntingtin forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity J. Cell Biol. 163 2003 109 118